These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2099071)

  • 41. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh.
    Sack DA; Clemens JD; Huda S; Harris JR; Khan MR; Chakraborty J; Yunus M; Gomes J; Siddique O; Ahmed F
    J Infect Dis; 1991 Aug; 164(2):407-11. PubMed ID: 1856488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.
    Russo P; Ligsay AD; Olveda R; Choi SK; Kim DR; Park JY; Park JY; Syed KA; Dey A; Kim YH; Lee SH; Kim J; Chon Y; Digilio L; Kim CW; Excler JL
    Vaccine; 2018 Jul; 36(29):4317-4324. PubMed ID: 29895500
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of a live oral cholera vaccine in human volunteers.
    Woodward WE; Gilman RH; Hornick RB; Libonati JP; Cash RA
    Dev Biol Stand; 1976; 33():108-12. PubMed ID: 782960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Kinetics of the vibriocidal antibody response to live oral cholera vaccines.
    Wasserman SS; Losonsky GA; Noriega F; Tacket CO; Castañeda E; Levine MM
    Vaccine; 1994 Aug; 12(11):1000-3. PubMed ID: 7975839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.
    Kenner JR; Coster TS; Taylor DN; Trofa AF; Barrera-Oro M; Hyman T; Adams JM; Beattie DT; Killeen KP; Spriggs DR
    J Infect Dis; 1995 Oct; 172(4):1126-9. PubMed ID: 7561195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Texas Star-SR: attenuated "Vibrio cholerae" oral vaccine candidate.
    Levine MM; Black RE; Clements ML; Young CR; Lanata C; Sears S; Honda T; Finkelstein R
    Dev Biol Stand; 1983; 53():59-65. PubMed ID: 6873477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand.
    Su-Arehawaratana P; Singharaj P; Taylor DN; Hoge C; Trofa A; Kuvanont K; Migasena S; Pitisuttitham P; Lim YL; Losonsky G
    J Infect Dis; 1992 Jun; 165(6):1042-8. PubMed ID: 1583321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Live oral cholera vaccine: evaluation of the clinical effectiveness of two strains in humans.
    Cash RA; Music SI; Libonati JP; Schwartz AR; Hornick RB
    Infect Immun; 1974 Oct; 10(4):762-4. PubMed ID: 4426706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.
    Svennerholm AM; Jertborn M; Gothefors L; Karim AM; Sack DA; Holmgren J
    J Infect Dis; 1984 Jun; 149(6):884-93. PubMed ID: 6736680
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.
    Lagos R; San Martin O; Wasserman SS; Prado V; Losonsky GA; Bustamante C; Levine MM
    Pediatr Infect Dis J; 1999 Jul; 18(7):624-30. PubMed ID: 10440439
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
    Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
    Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
    Suharyono ; Simanjuntak C; Witham N; Punjabi N; Heppner DG; Losonsky G; Totosudirjo H; Rifai AR; Clemens J; Lim YL
    Lancet; 1992 Sep; 340(8821):689-94. PubMed ID: 1355798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.
    Gotuzzo E; Butron B; Seas C; Penny M; Ruiz R; Losonsky G; Lanata CF; Wasserman SS; Salazar E; Kaper JB
    Infect Immun; 1993 Sep; 61(9):3994-7. PubMed ID: 8359923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh.
    Chowdhury F; Bhuiyan TR; Akter A; Bhuiyan MS; Khan AI; Hossain M; Tauheed I; Ahmed T; Islam S; Rafique TA; Siddique SA; Harun NB; Islam K; Clemens JD; Qadri F
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0007989. PubMed ID: 32176695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.
    Baik YO; Choi SK; Olveda RM; Espos RA; Ligsay AD; Montellano MB; Yeam JS; Yang JS; Park JY; Kim DR; Desai SN; Singh AP; Kim IY; Kim CW; Park SN
    Vaccine; 2015 Nov; 33(46):6360-5. PubMed ID: 26348402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of enteric-coated tablets as a whole cell inactivated vaccine candidate against Vibrio cholerae.
    Fernández S; Año G; Castaño J; Pino Y; Uribarri E; Riverón LA; Cedré B; Valmaseda T; Falero G; Pérez JL; Infante JF; García LG; Solís RL; Sierra G; Talavera A
    Travel Med Infect Dis; 2013; 11(2):103-9. PubMed ID: 23492079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.
    McCarty JM; Lock MD; Hunt KM; Simon JK; Gurwith M
    Vaccine; 2018 Feb; 36(6):833-840. PubMed ID: 29317118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reactogenicity and immunogenicity of oral cholera vaccine in Thai volunteers.
    Migasena S; Pitisuttitham P; Supanaranond W; Desakorn V; Prayurahong B; Suntharasamai P
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):423-8. PubMed ID: 3217824
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.